Unione Europea - italiano - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant può essere usato in monoterapia o in combinazione con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 50 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.814 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 1.365 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 100 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.629 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 2.73 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 30 mg, lactosum monohydricum 56.06 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 126 - 189 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 90 mg, lactosum monohydricum 168.17 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 378 - 567 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

takeda pharma ag - brigatinibum - compresse rivestite con film - brigatinibum 180 mg, lactosum monohydricum 336.33 mg, cellulosum microcristallinum, carboxymethylamylum natricum a corresp. natrium 756 - 1134 µg, silica hydrophobica colloidalis, magnesii stearas, Überzug: talcum, macrogolum 3350, poly(alcohol vinylicus), e 171 pro compresso obducto. - non tumori polmonari a piccole carcinoma polmonare (nsclc) - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - compresse rivestite con film - comprimé pelliculé: baricitinibum 2 mg, mannitolum 52 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - baricitinibum - compresse rivestite con film - comprimé pelliculé: baricitinibum 4 mg, mannitolum 50 mg, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, pellicule: poly(alcohol vinylicus), macrogolum, talcum, lecithinum ex soja, color.: e 171, e 172 (rubrum), pro compresso obducto, natrium 0.7608 mg. - polyarthrite rhumatoïde / dermatite atopique / covid 19 / alopecia areata - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopica - altri preparati dermatologici - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - carcinoma, polmone non a piccole cellule - agenti antineoplastici - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.